Pancreatic "supercyst".
- Published in:
- 2025
- By:
- Publication type:
- Case Study
Works matching AU Harrer, Dennis Christoph
Results: 15
1
2
Unusually swift response of relapsed Burkitt leukemia to R‐DHAP.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 1003, doi. 10.1002/jha2.501
- By:
- Publication type:
- Article
3
MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck.
- Published in:
- Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1553331
- By:
- Publication type:
- Article
4
IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1185618
- By:
- Publication type:
- Article
5
Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion.
- Published in:
- Cells (2073-4409), 2025, v. 14, n. 12, p. 901, doi. 10.3390/cells14120901
- By:
- Publication type:
- Article
6
CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 23, p. 3839, doi. 10.3390/cells11233839
- By:
- Publication type:
- Article
7
Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.755439
- By:
- Publication type:
- Article
8
CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy.
- Published in:
- 2023
- By:
- Publication type:
- Literature Review
9
Drug Repurposing by Tumor Tissue Editing.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.900985
- By:
- Publication type:
- Article
10
Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.886436
- By:
- Publication type:
- Article
11
Apheresis for chimeric antigen receptor T‐cell production in adult lymphoma patients.
- Published in:
- Transfusion, 2022, v. 62, n. 8, p. 1602, doi. 10.1111/trf.17030
- By:
- Publication type:
- Article
12
Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β Release.
- Published in:
- Cancers, 2024, v. 16, n. 15, p. 2737, doi. 10.3390/cancers16152737
- By:
- Publication type:
- Article
13
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance.
- Published in:
- Cancers, 2024, v. 16, n. 1, p. 180, doi. 10.3390/cancers16010180
- By:
- Publication type:
- Article
14
Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.
- Published in:
- Cancers, 2022, v. 14, n. 20, p. 5033, doi. 10.3390/cancers14205033
- By:
- Publication type:
- Article
15
Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2023.1289222
- By:
- Publication type:
- Article